Dantrolene in the Treatment of Refractory Hyperthermic Conditions in Critical Care: A Multicenter Retrospective Study  

作　　者：Shonali C. Pawar Henry Rosenberg Robert Adamson Jennifer A. LaRosa Ronald Chamberlain 

机构地区：[1]Department of Surgery, Saint Barnabas Medical Center, Livingston, USA [2]Department of Medical Education and Clinical Research, Saint Barnabas Medical Center, Livingston, USA [3]Corporate Pharmaceutical Sciences, Barnabas Health Care, Livingston, NJ, USA [4]Department of Pulmonary and Critical Care Medicine, Newark Beth Israel Medical Center, Newark, NJ, USA

出　　处：《Open Journal of Anesthesiology》2015年第4期63-71,共9页麻醉学期刊（英文）

摘　　要：Purpose: To examine the use of intravenous dantrolene in hospitalized patients. Materials and Methods: Medical Records of patients treated with intravenous dantrolene between 2007 and 2012 at 6 teaching hospitals were reviewed. Temperature, muscle rigidity, creatine kinase levels, and mortality were assessed in association with dantrolene use. Results: Twenty-five patients received intravenous dantrolene, 9 patients with neuroleptic malignant syndrome (NMS), 8 with hyperthermia due to sepsis, 4 with NMS and sepsis, 2 for malignant hyperthermia (MH), and 2 with hypermetabolic syndrome associated with juvenile diabetic ketoacidosis. Dantrolene was administered as a bolus of 1 - 3 mg/kg. Core temperature decreased after dantrolene administration in all groups but significant only for MH, NMS cases (Pre 102.3 ± 0.9&degF vs. Post 99.5 ± 0.9&degF;p Conclusion: Dantrolene was associated with reductions in temperature and rigidity in hyperthermia of diverse origins in patients admitted to Intensive care settings.Purpose: To examine the use of intravenous dantrolene in hospitalized patients. Materials and Methods: Medical Records of patients treated with intravenous dantrolene between 2007 and 2012 at 6 teaching hospitals were reviewed. Temperature, muscle rigidity, creatine kinase levels, and mortality were assessed in association with dantrolene use. Results: Twenty-five patients received intravenous dantrolene, 9 patients with neuroleptic malignant syndrome (NMS), 8 with hyperthermia due to sepsis, 4 with NMS and sepsis, 2 for malignant hyperthermia (MH), and 2 with hypermetabolic syndrome associated with juvenile diabetic ketoacidosis. Dantrolene was administered as a bolus of 1 - 3 mg/kg. Core temperature decreased after dantrolene administration in all groups but significant only for MH, NMS cases (Pre 102.3 ± 0.9&degF vs. Post 99.5 ± 0.9&degF;p Conclusion: Dantrolene was associated with reductions in temperature and rigidity in hyperthermia of diverse origins in patients admitted to Intensive care settings.

关 键 词：DANTROLENE MALIGNANT HYPERTHERMIA NEUROLEPTIC MALIGNANT Syndrome SEPSIS 

分 类 号：R5[医药卫生—内科学]